These findings support the notion that ATR, CHK1 and WEE1 inhibitors would sensitise tumours that are intrinsically resistant to PARPi, by virtue of HRP genotype or acquire resistance through restoration of HRR function clinically. The gene discussed is CHEK1; the disease is neoplasm.